Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has achieved a regulatory milestone with its clinical trial application for SKB571, an innovative antibody-drug conjugate (ADC), being accepted for review by China’s National Medical Products Administration (NMPA). SKB571 is designed to target a spectrum of cancers, including those of the lung and the digestive system.
In a strategic update to its partnership with Merck, Sharp & Dohme (MSD), Kelun-Biotech has granted the US pharmaceutical major an exclusive option to develop SKB571 on a global scale, with the exception of Greater China, for a consideration of USD 37.5 million. This agreement leaves Kelun-Biotech with full development, usage, manufacturing, and commercialization rights for the drug within mainland China, Hong Kong, and Macau. – Flcube.com
